Caribou Biosciences: CB-010, chRDNA Technology Continue To Show Promise In Gene Editing
Caribou Biosciences focuses on allogeneic CAR-T therapies for hematological cancers. Read why I now taper my rating for CRBU ...
Caribou Biosciences to Present Preclinical Data Supporting Development of CB-010 for Lupus at the American College of Rheumatology Convergence 2024
The poster will highlight the preclinical data and key elements of the clinical trial design that supported the investigational new drug (IND) clearance to evaluate CB-010 in the GALLOP Phase 1 ...
Business Insider29d
Caribou Biosciences Announces the FDA has Granted Fast Track Designations to CB-010 in Refractory SLE and to CB-012 in Relapsed or Refractory AML
Fast Track designation is designed to expedite clinical development and regulatory review timelines -- -- Additional FDA designation for CB-010 following earlier RMAT and Fast Track designations ...
7 Top Gene-Editing Stocks to Buy
Analysts at Precedence Research expect the gene-editing market to grow 15.7% annually and reach $29.9 billion by 2032, ...
Sporting News5d
Chargers vs. Chiefs Series History: When was the last time L.A. beat the champs?
The Chargers have endured a losing streak against the Kansas City Chiefs and ending that is likely at the top of Jim Harbaugh ...
Yahoo Finance7d
Caribou Biosciences to Present Preclinical Data Supporting Development of CB-010 for Lupus at the American College of Rheumatology Convergence 2024
CB-010 is the lead clinical-stage product candidate from Caribou’s allogeneic CAR-T cell therapy platform, and it is being evaluated in patients with relapsed or refractory B cell non-Hodgkin ...
Yahoo Finance29d
Caribou Biosciences Announces the FDA has Granted Fast Track Designations to CB-010 in Refractory SLE and to CB-012 in Relapsed or Refractory AML
CB-010, an allogeneic anti-CD19 CAR-T cell therapy, will be evaluated in the GALLOP Phase 1 clinical trial in patients with lupus nephritis (LN) and extrarenal lupus (ERL), subcategories of SLE.
Mena FN7d
Caribou Biosciences To Present Preclinical Data Supporting Development Of CB-010 For Lupus At The American College Of Rheumatology Convergence 2024
The poster will highlight the preclinical data and key elements of the clinical trial design that supported the investigational new drug (IND) clearance to evaluate CB-010 in the GALLOP Phase 1 ...
Mena FN29d
Caribou Biosciences Announces The FDA Has Granted Fast Track Designations To CB-010 In Refractory SLE And To CB-012 In Relapsed Or Refractory AML
CB-010 GALLOP Phase 1 trial in patients with LN and ERL is on track to initiate by YE 2024 -- -- CB-012 AMpLify Phase 1 trial advancing in dose escalation -- BERKELEY, Calif., Sept. 03 ...
Stockhouse29d
Caribou Biosciences Announces the FDA has Granted Fast Track Designations to CB-010 in Refractory SLE and to CB-012 in Relapsed or Refractory AML
CB-010 GALLOP Phase 1 trial in patients with LN and ERL is on track to initiate by YE 2024 -- -- CB-012 AMpLify Phase 1 trial advancing in dose escalation -- BERKELEY, Calif., Sept. 03, 2024 (GLOBE ...